"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 5 | 8 |
| 2012 | 4 | 3 | 7 |
| 2013 | 4 | 4 | 8 |
| 2014 | 4 | 3 | 7 |
| 2015 | 5 | 6 | 11 |
| 2016 | 4 | 0 | 4 |
| 2017 | 4 | 0 | 4 |
| 2018 | 7 | 2 | 9 |
| 2019 | 2 | 4 | 6 |
| 2020 | 4 | 6 | 10 |
| 2021 | 10 | 9 | 19 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 9 | 9 |
| 2024 | 3 | 6 | 9 |
| 2025 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Inhibitory activities of monoclonal antibodies against Staphylococcus aureus clumping factor A. mBio. 2025 Oct 08; 16(10):e0219725.
-
Long-lasting B cell convergence to distinct broadly reactive epitopes following vaccination with chimeric influenza virus hemagglutinins. Immunity. 2025 Apr 08; 58(4):980-996.e7.
-
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 02 05; 80(1):223-227.
-
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
-
Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines. JCI Insight. 2025 Jan 09; 10(4).
-
Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles. Vaccine. 2025 02 06; 46:126668.
-
Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression. PLoS Pathog. 2024 Dec; 20(12):e1012739.
-
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan; 637(8048):1218-1227.
-
Measures of Population Immunity Can Predict the Dominant Clade of Influenza A (H3N2) in the 2017-2018 Season and Reveal Age-Associated Differences in Susceptibility and Antibody-Binding Specificity. Influenza Other Respir Viruses. 2024 11; 18(11):e70033.
-
Vaccination against rapidly evolving pathogens and the entanglements of memory. Nat Immunol. 2024 Nov; 25(11):2015-2023.